SALT LAKE CITY, July 6, 2021 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused
on metabolic and endocrine disorders, today announced that the
Company will present at the Ladenburg Thalmann Healthcare
Conference. The conference will be held virtually. Presentation
details are below.
Ladenburg Thalmann Healthcare Conference July 13-14
Presentation time: July 13, 2021 starting at 11:00am ET
The webcast of this presentation will also be available on
Lipocine's corporate website under "Events & Presentations" in
the Investors section.
About Lipocine Inc.
Lipocine Inc. is a clinical-stage biopharmaceutical company
focused on metabolic and endocrine disorders using its proprietary
drug delivery technologies. Lipocine's clinical development
pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN
1154, and LPCN 1107. TLANDO, a novel oral prodrug of testosterone
containing testosterone undecanoate, has received tentative
approval from the FDA for conditions associated with a deficiency
of endogenous testosterone, also known as hypogonadism, in adult
males. LPCN 1144, an oral prodrug of bioidentical
testosterone, recently completed a proof-of-concept clinical study
demonstrating the potential utility in the treatment of
non-cirrhotic NASH. LPCN 1144 is currently being studied in a
Phase 2 clinical study. TLANDO XR, a novel oral prodrug of
testosterone, originated and is being developed by Lipocine as a
next-generation oral testosterone product with potential for
once-daily dosing. In a phase 2 clinical evaluation when
administered as once daily or twice daily TLANDO XR met the typical
primary and secondary end points. LPCN 1148 is an oral prodrug of
bioidentical testosterone targeted for the treatment of cirrhosis.
LPCN 1107 is potentially the first oral hydroxyprogesterone
caproate product candidate indicated for the prevention of
recurrent preterm birth and has been granted orphan drug
designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted
for the treatment of post-partum depression. For more
information, please visit www.lipocine.com.
View original content to download
SOURCE Lipocine Inc.